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AbstrACt
Objectives Despite HIV testing recommendations 
published by the Federal Office of Public Health (FOPH) 
since 2007, many individuals living with HIV are diagnosed 
late in Switzerland. The aim of this study is to examine the 
effect of the 2013 FOPH HIV testing recommendations on 
HIV testing rates.
setting Ten clinical services at Lausanne University 
Hospital, Lausanne, Switzerland.
Participants Patients attending between 1 January 2012 
and 31 December 2015.
Design Retrospective analysis using two existing hospital 
databases. HIV testing rates calculated as the percentage 
of tests performed (from the Immunology Service 
database) per number of patients seen (from the central 
hospital database).
Primary and secondary outcome measures The 
primary outcome was testing rate change following the 
2013 FOPH testing recommendations, comparing testing 
rates 2 years before and 2 years after their publication. 
Secondary outcomes were demographic factors of patients 
tested or not tested for HIV.
results 147 884 patients were seen during the study 
period of whom 9653 (6.5%) were tested for HIV, with 
34 new HIV diagnoses. Mean testing rate increased from 
5.6% to 7.8% after the recommendations (p=0.001). 
Testing rate increases were most marked in services 
involved in clinical trials on HIV testing, whose staff had 
attended training seminars on testing indications and 
practice. Testing rates were lower among older (aged >50 
years), female and Swiss patients compared with younger, 
male and non-Swiss patients, both globally (p=0.001) and 
in specific clinical services.
Conclusions This simple two-database tool demonstrates 
clinical services in which HIV testing practice can be 
optimised. Improved testing rates in services involved in 
clinical trials on testing suggest that local engagement 
complements the effect of national recommendations. 
While, overall, HIV testing rates increased significantly 
over time, testing rates were lower among patients with 
similar demographic profiles to individuals diagnosed late 
in Switzerland.
IntrODuCtIOn 
HIV testing is key in diagnosing individuals 
living with HIV and in enabling engage-
ment in care, antiretroviral treatment and 
viral suppression. Testing individuals early 
in infection reduces consequent morbidity, 
mortality, healthcare costs and onward trans-
mission.1 HIV testing recommendations have 
been published in Switzerland by the Federal 
Office of Public Health (FOPH) since 2007,2 
with updates in 2010, 2013 and 2015.3–5 The 
strengths and limitations of this study
 ► A simple two-database tool was used to calcu-
late HIV testing rates over a wide range of clinical 
services.
 ► The single-centre design enabled knowledge of 
clinical service structure and therefore the profile of 
patients being examined.
 ► Testing rates could be compared within clinical ser-
vices over time.
 ► Although the two-database tool is simple and ro-
bust, it does not provide a ‘margin of improvement’ 
for testing rates, as it examines only testing rates 
and not the parameters which could influence these.
 ► Due to the retrospective nature of this study, the de-
nominator taken to calculate testing rates was the 
number of patients visiting each service, rather than 
the number of patients visiting the service who pre-
sented testing indications. Changes in testing rates 
within a service could therefore be due to changes 
in the number of patients meeting screening criteria 
rather than changes in testing practice per se.
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recommendations propose physician-initiated counsel-
ling and testing (PICT) which is targeted and opt-in, and 
requires testing to be offered to patients explicitly before 
being performed. The FOPH recommendations present 
the situations in which HIV testing is indicated, notably, 
symptoms and signs of acute HIV infection, AIDS-de-
fining illness, HIV indicator diseases and groups at high 
risk of HIV acquisition. The physician is responsible for 
recognising these situations in clinical practice.
In contrast to PICT, the HIV testing recommendations 
of the USA,6 France7 and the UK8 propose non-targeted 
and opt-out testing in healthcare settings in which local 
HIV seroprevalence is above a certain threshold (0.1% in 
the USA and France, 0.2% in the UK). In this case, testing 
is performed regardless of clinical presentation or risk 
factors, unless the patient explicitly declines. Patient-re-
lated, doctor-related and system-related barriers exist to 
both targeted and non-targeted testing approaches9–11 
and may delay HIV diagnosis in positive individuals. In 
Switzerland, almost half of the patients newly diagnosed 
with HIV are identified late, with CD4 counts below 350 
cells/mm3 or an AIDS-defining condition,12 suggesting 
that testing practice is suboptimal.
In 2012, our group examined the effect of the 2010 
FOPH HIV testing recommendations on the testing 
rates of selected clinical services at Lausanne University 
Hospital (LUH), Lausanne, and reported that there was 
no significant change in HIV testing practice associated 
with the recommendations’ publication.13 Among the 
clinical services, the emergency department (ED) and 
the oncology service had particularly low testing rates at, 
respectively, 1% and 4% of all patients seen.13 Following 
the 2010 FOPH recommendations, which specifically 
mentioned the ED as a service in which HIV testing should 
take place, we observed that 82% of ED doctors in French-
speaking Switzerland were unaware of national HIV testing 
recommendations and that even those aware did not always 
propose testing when indicated.14 After providing training 
seminars on testing indications and the practical aspects of 
testing to address this lack of awareness, we observed other 
ED doctor-related barriers to proposing testing, notably, a 
preference to focus on the reason(s) for presenting over 
discussing HIV.11 In the oncology service, we observed 
that HIV testing of patients diagnosed with AIDS-defining 
cancers (ADCs) was not universal and was especially poor 
among patients with invasive cervical cancer (HIV testing 
rate 11%).15 To investigate barriers to HIV testing in this 
service, we provided information seminars for doctors and 
nurses on HIV testing indications and testing practice, and 
examined HIV testing rates among patients newly diag-
nosed with non-ADCs. Among 239 patients enrolled in this 
study, the HIV testing rate increased from 4% (baseline) 
to 18%, and patient acceptance of HIV testing offered was 
high (91%).16
In November 2013, the FOPH HIV testing recommen-
dations were updated, differing from the 2010 recom-
mendations in three main ways.4 First, testing indications 
were graded such that HIV testing should be expressly 
recommended (for acute HIV infection and AIDS-defining 
conditions), recommended (for HIV indicator diseases, 
following the results of the HIV Indicator Diseases across 
Europe Study17) or proposed (where not diagnosing HIV 
could have severe consequences or for individuals at 
risk of HIV acquisition). Second, patients undergoing 
immunosuppressive therapy, including chemotherapy, 
were included as a group in whom HIV testing should be 
proposed. Third, it was stated explicitly that not performing 
an HIV test when indicated could have medicolegal 
consequences.
The aim of this study was to repeat the analysis of HIV 
testing practice in selected clinical services at our centre, 
this time examining the effect on testing rates of the 2013 
FOPH HIV testing recommendations.
MethODs
Patient and public involvement
Patients and public were not involved in the design of 
this study. The research question on HIV testing prac-
tice arose from the experience of some of our patients 
attending our HIV OP service of presenting late with HIV 
despite having visited different services at our hospital 
during the years preceding their HIV diagnosis.
All patient data used were stripped of identifiers prior 
to analysis.
hIV testing
HIV testing performed in the Immunology Service uses a 
fourth generation screening assay to detect anti-HIV1/2 
antibodies and p24 antigen (Cobas Elecsys HIV combi 
PT, Roche Diagnostics, Rotkreutz, Switzerland). Reactive 
samples undergo confirmation assays (p24 neutralisation 
assay and a line immunoassay for HIV-1/2 antibodies) 
before the release of a positive result as previously 
described.13 All HIV tests performed are entered into 
the Immunology Service database, together with the 
requesting service, date of request, date of test and result.
study setting
The study was retrospective and single-centre, performed 
at LUH, Lausanne, Switzerland, a 1500-bed teaching 
hospital where local HIV seroprevalence is estimated 
to be between 0.2% (estimated from Swiss HIV Cohort 
Study data) and 0.5% (UNAIDS estimation).18 19 At this 
centre, doctors attend regular educational seminars as is 
standard in a teaching hospital but without necessarily a 
focus on HIV.
Ten clinical services were selected for analysis: general 
internal medicine inpatients (IP), neurology IP, cardi-
ology IP, intensive care units, ED, psychiatry IP (excluding 
services for substance misuse where HIV testing is 
routine), oncology outpatients (OP), dermatology IP and 
OP, ear, nose and throat (ENT) surgery IP and OP, and 
non-ENT surgery IP (including vascular, cardiothoracic, 
gastrointestinal, maxillofacial surgery, urology and neuro-
surgery). The services were selected for ≥1 of the following 
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reasons: (1) receiving patients likely to present with HIV 
testing indications by specialty3 4; (2) previous target of 
educational interventions (ED, oncology service11 14 16 20); 
and (3) enabling comparison with testing rates prior to 
2012.13 Due to the retrospective nature of this study, it 
was not possible to identify patients presenting specific 
HIV testing indications. In order to make the number of 
patients presenting as close as possible to the number of 
patients presenting with testing indications, we restricted 
our analysis to patients presenting to selected subunits 
within each clinical service. For example, for the cardi-
ology service, we included subunits receiving acute isch-
aemic heart disease admissions and excluded subunits 
related to congenital anomalies or cardiac transplant 
work-ups.
Between 2012 and 2015, the oncology service under-
went expansion, resulting in some units seeing a 
substantial increase in patient turnover. For the current 
study, we restricted analysis to units examined previ-
ously13 and those taking part in clinical trials on HIV 
testing.
study design
All patients aged ≥16 years old presenting to the 
selected clinical services between 1 January 2012 and 
31 December 2015 were eligible for inclusion. Using 
the central hospital database, the number of patients 
attending each service was obtained over four 12-month 
blocks, corresponding to each calendar year. Dates of 
all hospital visits and patient demographic parameters 
(age, sex, origin) were also obtained from this database. 
The number of HIV tests performed during the same 
12-month blocks was obtained from the Immunology 
Service database.
For each 12-month block, HIV testing rates were 
calculated as the percentage of tests performed per 
number of patients seen. For the testing rate calcula-
tions, the number of patients rather than the number 
of clinical episodes was taken as the denominator, to 
avoid underestimating testing rates in clinical services 
which may see the same patient several times, notably 
in the OP sector.
For the ED, to examine the effect of local clinical 
trials and associated educational interventions on HIV 
testing, testing rates were calculated monthly in addition 
to 12-monthly. For 12-monthly testing rates, the entire 
service was analysed whereas for the monthly testing 
rates, analysis was restricted to the sections involved in 
the clinical trials. In the oncology service, testing rates 
were additionally compared between 2012 and 2013, in 
line with a clinical trial which ran from July to October 
2013.16 However, as the 2013 FOPH recommendations 
introduced ‘proposing’ testing to all patients undergoing 
immunosuppressive treatment, the specific effect of clin-
ical trials after 2013 was not examined in this study. The 
results of these trials will be published elsewhere (manu-
script in preparation).
Positive hIV tests
Occasionally, an HIV test (the fourth generation 
screening assay described above) is requested erroneously 
for patients of known positive HIV status instead of viral 
load. For all tests conducted and confirmed as positive, 
therefore, test dates were cross-referenced with electronic 
medical records to determine whether each positive test 
was a new or a known positive case.
statistical analyses
Data are presented as means with SD, medians with 
IQR and as percentages. Means were compared using 
Student’s t-test and proportions compared using the χ2 
test using two-way contingency tables. To examine the 
effect of the 2013 FOPH HIV testing recommendations, 
testing rates for each clinical service, and overall, were 
examined during the 2 years before and the 2 years after 
the publication of the recommendations (1 January 2012 
to 31 December 2013 and 1 January 2014 to 31 December 
2015) and then compared. Although the updated FOPH 
recommendations were published in November 2013, the 
month of December 2013 was included in the ‘before’ 
analysis given that there is usually a lag period of at least 
1 month between recommendations being published 
and being read and/or implemented.13 Oncology 
service testing rates were additionally compared between 
1 January to 31 December 2012 and 1 January to 31 
December 2013.
In our 2012 report on testing, we commented that patient 
origin may have an effect on testing, based on the obser-
vation that the medical OP service not examined in the 
present study had a particularly high percentage of patients 
from countries with high HIV prevalence (estimated to be 
up to 65%13). We therefore examined the effect of patient 
age, sex and origin on testing rates in each clinical service, 
and overall. Patient origin was categorised as Swiss, from 
neighbouring countries (France, Germany, Austria, Italy 
and Lichtenstein), from sub-Saharan Africa (SSA) and 
‘other’, comprising countries not falling into the first three 
categories. When patient numbers were low in specific 
origin categories, analyses were performed by grouping 
patients in the latter three categories as ‘non-Swiss’. 
Patients lacking data on origin were removed from analyses 
provided the proportion of patients removed was <10%; if 
the percentage was ≥10% in a specific service, analysis of 
origin data was not performed.
All analyses were performed using Microsoft Excel 2008 
(Microsoft, Redmond, Washington, USA).
results
study population
During the 4-year study period, 147 884 patients were seen 
at the 10 clinical services examined. Patient demographic 
profile did not change significantly during this time. In 
total, 9653 patients underwent HIV testing (global HIV 
testing rate 6.5%). Online supplementary table 1 shows 
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the demographic characteristics of patients tested and 
not tested.
The total number of patients attending the 10 clinical 
services increased progressively over the 4-year period 
from 34 861 to 36 460 patients but the difference in 
the number of patients attending before versus after 
the 2013 FOPH recommendations was not significant 
(p=0.14).
hIV tests and testing rates
The total number of tests performed increased over the 
4-year period, with a mean of 2220±94.5 tests before and 
2803±171 tests after the 2013 FOPH recommendations 
(p=0.001). The global testing rates (for all clinical services 
together) also increased significantly between before and 
after the 2013 recommendations from 5.6%±0.2% (2012–
2013) to 7.8%±0.4% (2014–2015) (p=0.002) (table 1 and 
figure 1). Testing rate increases were particularly marked 
in the ED (from 4.2%±0.3% to 5.6%±0.4%, p=0.001, 
table 1) and the oncology service (from 3.8%±0.8% to 
23.6%±7.4%, p=0.0001, figure 1).
Positive hIV tests
In total, 18 new HIV diagnoses (0.46% of tests performed) 
were made between 2012 and 2013, and 16 new diagnoses 
(0.33% of tests performed) were made between 2014 and 
2015 (table 1). The demographic characteristics have 
not differed significantly between the two time periods 
and so are presented here for all 34 newly diagnosed 
patients: median age was 42 years (IQR 34–48), 28 (82%) 
were men, 14 (41%) were Swiss and 20 were non-Swiss, 
including eight (24%) from SSA. Median CD4 count at 
diagnosis was 188 cells/mm3 (IQR 32–363).
There were 30 erroneous repeat HIV tests in patients 
of known positive status. However, retesting enabled two 
patients who had been lost to follow-up to be reintegrated 
into care.
The rate of positive tests out of tests performed 
remained stable with time in each service, at between 
0% and 0.9% (table 1), with no change between before 
and after the 2013 FOPH recommendations (p=0.77). 
There were no positive tests among patients attending 
the services of cardiology, surgery and oncology, 
although testing rates in the cardiology and surgery 
services were at the lower end of all services studied 
(figure 1).
effect of patient demographic profile on testing
The breakdown of patients by age, sex and origin was 
examined using the two study databases. Globally, the 
proportion of patients attending the 10 clinical services 
who were aged below 50 did not change over the 4-year 
period, with a mean proportion of 31.8%±0.24%. 
Equally, the proportion of patients aged below 50 
who were tested for HIV remained stable with a mean 
proportion of 51.3%±1.36%. However, in some services, 
the proportion of patients tested was higher among 
patients aged below 50 than among older patients T
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(table 2). Testing rates were also significantly higher 
among male than among female patients in several clin-
ical services and overall (table 2).
To examine patient origin, patients were pooled as 
Swiss and non-Swiss as the percentage of specific groups 
mentioned in the 2013 recommendations, notably 
patients from SSA, was low (online supplementary table 
1). In several services, and overall, testing rates were 
significantly higher among non-Swiss compared with 
Swiss patients (table 2).
In the neurology service, testing practice changed with 
time. While there was a significant increase in testing 
rates between 2012 and 2015, the testing rates increased 
progressively among patients aged below 50 years while 
the testing rate among older patients remained stable 
(online supplementary figure 1). While progressive 
increases in testing rates were observed over time in other 
Figure 1 Absolute number of HIV tests requested (panel 
A) and HIV testing rate (panel B) with time in the 10 clinical 
services studied. Asterisks indicate significant differences 
in rates (p<0.01) between before (2012–2013) and after 
(2014–2015) the publication of the Federal Office of Public 
Health HIV testing recommendations in November 2013. ED, 
emergency department; ENT, ear, nose and throat service; 
ICU, intensive care units.
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clinical services, no such increase was observed among 
patients with a specific demographic profile.
effect of local interventions
During local educational interventions in ED sections 
involved in clinical trials, monthly testing rates exceeded 
the mean rate for the ED as a whole (figure 2). In the 
oncology service, testing rates increased significantly 
from 12% in 2012 to 16% in 2013 (p=0.0005), when 
training seminars on HIV testing were provided to 
medical and nursing staff, in addition to increasing 
between before and after the 2013 recommendations as 
described above.
DIsCussIOn
We have applied the same two-database tool with which 
we examined the effect of the 2010 FOPH recommenda-
tions13 to examine the effect of the 2013 FOPH recom-
mendations at our centre. We observed a global increase 
in HIV testing following the 2013 recommendations, with 
significant increases in clinical services receiving educa-
tional interventions in the context of clinical trials on 
testing. As these services had among the lowest testing 
rates prior to 2012, our observed increase suggests that 
local engagement complements the effect of national 
testing recommendations.
As we observed in our previous study, testing rates 
in the neurology, internal medicine and psychiatry 
IP services were higher than those in other services.13 
These three services see patients presenting with many 
of the conditions listed as testing indications in the 
2013 recommendations. Further, the neurology and 
internal medicine IP services make up two of the three 
principal services which receive patients admitted 
via the ED (OH, departmental data). Conversely, the 
cardiology service had relatively low testing rates. While 
some patients attending this service may have presented 
with non-vascular cardiac pathology or with vascular 
pathology presenting non-acutely, the low testing rates 
are surprising given accumulating evidence of a patho-
physiological link between HIV infection and endothe-
lial damage.21 22 However, while myocardial infarction, 
together with cerebrovascular events and peripheral 
arterial disease, has been mentioned as an indication 
for HIV testing in the 2010 FOPH recommendations,3 
it is not mentioned in the 2013 update,4 and patients 
presenting with acute coronary syndromes to the 
LUH cardiology service are not tested routinely (OM, 
personal communication). Among cardiology patients 
who were tested over the 4-year period, the rate of new 
HIV diagnoses was zero. The finding that testing rates 
have been lower among dermatology patients than 
among surgery patients is also surprising. However, 
this may be explained by the high patient denominator 
in the dermatology service, and the possibility that 
patients seen have not presented HIV testing indica-
tions. All these observations highlight the importance 
of applying the two-database tool only when service 
structure (patient diagnosis profile, referral source, 
etc) is known, so that testing rates can be interpreted 
meaningfully.
In the ED, the testing rates were markedly higher than 
those reported previously.13 14 In addition to the signifi-
cant increase between before and after the recommenda-
tions, we observed a possible effect of local interventions 
in the form of training seminars and clinical trials. The 
positive effect of local interventions on HIV testing prac-
tice has been described in a London university hospital 
Figure 2 Monthly HIV testing rates in the emergency department (ED) sections involved in clinical trials on HIV testing and 
the temporal relationship between HIV testing rates and clinical trials (black bar groups 1 and 3), other training seminars (black 
bar group 2), and the publication of Federal Office of Public Health HIV testing recommendations (arrows 2013 and 2015). 
The dotted line indicates the mean testing rate for all ED sections for the year 2012, the first year of this study. 1Clinical trial 
examining patients’ understanding of and attitudes to HIV testing in the ED.20 2Training seminars on testing following the 
publication of low awareness of HIV testing recommendations among ED doctors in French-speaking Switzerland.14 3Clinical 
trial examining patient-associated and doctor-associated barriers to HIV testing in the ED and patient acceptance of rapid HIV 
testing.11
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ED setting, the authors adding that constant commitment 
was required to achieve sustainability.23
We observed that testing was significantly higher 
among non-Swiss than Swiss patients in some services. 
Testing rates differed with other demographic charac-
teristics, being higher among male patients and those 
aged below 50 years. Due to the retrospective design 
of this study, we could not identify why testing rates 
among Swiss, older and female patients were lower in 
some services, and it is possible that these patients did 
not present HIV testing indications. It is noteworthy, 
however, from Swiss HIV Cohort Study data, that older 
age and female sex were observed as risk factors for 
late presentation among patients newly diagnosed with 
HIV between 2009 and 2012.12 Perhaps future updates 
of Swiss HIV testing recommendations should mention 
the demographic profiles of individuals at risk of late 
presentation, to avoid undertesting patients not classi-
cally considered as high risk.1
This study has limitations. An important limitation 
was that the denominator used to calculate testing rates 
was taken as the number of patients presenting, with no 
means of identifying the number of patients who had HIV 
testing indications. We restricted our analysis to well-char-
acterised subunits within each clinical service to optimise 
the percentage of patients presenting who had testing 
indications but this remains a limitation of our study. As 
with any single-centre study, the results presented may 
not be applicable to other settings, particularly if service 
structures differ. Although this two-database tool enables 
testing rates to be calculated and compared over time, 
it does not provide a ‘margin for improvement’ in each 
setting. We have no data on the percentage of healthcare 
professionals aware of the FOPH HIV testing recom-
mendations, outside the ED setting, or the percentage 
of patients presenting testing indications who were not 
tested. In this way, while we observed improved testing 
rates with time, it is possible that this occurred through 
factors unrelated to the publication of the 2013 FOPH 
HIV testing recommendations.
In conclusion, we have described a simple two-data-
base method of measuring testing rates which enables 
healthcare centres to identify clinical services in which 
testing rates can be optimised and to follow progress 
with time. HIV testing rates increased at our centre over 
time, particularly in services involved in clinical trials on 
testing. The lower testing rates we observed among Swiss, 
older and female patients merit examination, given that 
patients lacking the ‘classical’ demography for HIV acqui-
sition should still be included in testing initiatives if they 
present with indications.
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